Efficacy and Safety of Fexofenadine HCl in Japanese Patients with Chronic Idiopathic Urticaria
暂无分享,去创建一个
Fexofenadine is a nonsedating antihistamine, which has been approved by the FDA for treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. The purpose of this double-blind dose-finding study was to determine the optimal dose of fexofenadine in Japanese patients with chronic idiopathic urticaria. In addition, the results of this study were compared with those from two double-blind studies conducted in North America [1, 2] to examine ethnic differences in terms of the efficacy (assessed by comparing symptom scores for itching) and safety of fexofenadine in the two populations.
[1] A. Kaplan,et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. , 1999, The Journal of allergy and clinical immunology.